Appropriate primary prevention of cardiovascular disease: Does this mean more or less statin use?

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Treatment with HMG-CoA reductase inhibitors, commonly known as statins, is beneficial for people at high risk of a cardiovascular event. However, guidelines recommend against routine statin treatment for those with a lower risk. They also recommend waiting until after 45 years of age to assess cardiovascular risk in healthy individuals. Aboriginal and Torres Strait Islander people should be assessed from age 35 years. These recommendations are based on current evidence of who is more likely to benefit from statin treatment.

Original languageEnglish
Pages (from-to)169-172
Number of pages4
JournalAustralian Prescriber
Volume34
Issue number6
DOIs
Publication statusPublished - 2011

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Primary Prevention
Cardiovascular Diseases
Guidelines

Cite this

@article{39ff75aca7db43d3a7b5cc8677293b03,
title = "Appropriate primary prevention of cardiovascular disease: Does this mean more or less statin use?",
abstract = "Treatment with HMG-CoA reductase inhibitors, commonly known as statins, is beneficial for people at high risk of a cardiovascular event. However, guidelines recommend against routine statin treatment for those with a lower risk. They also recommend waiting until after 45 years of age to assess cardiovascular risk in healthy individuals. Aboriginal and Torres Strait Islander people should be assessed from age 35 years. These recommendations are based on current evidence of who is more likely to benefit from statin treatment.",
author = "Jane Smith",
year = "2011",
doi = "10.18773/austprescr.2011.085",
language = "English",
volume = "34",
pages = "169--172",
journal = "Australian Prescriber",
issn = "0312-8008",
publisher = "National Prescribing Service",
number = "6",

}

Appropriate primary prevention of cardiovascular disease : Does this mean more or less statin use? / Smith, Jane.

In: Australian Prescriber, Vol. 34, No. 6, 2011, p. 169-172.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Appropriate primary prevention of cardiovascular disease

T2 - Does this mean more or less statin use?

AU - Smith, Jane

PY - 2011

Y1 - 2011

N2 - Treatment with HMG-CoA reductase inhibitors, commonly known as statins, is beneficial for people at high risk of a cardiovascular event. However, guidelines recommend against routine statin treatment for those with a lower risk. They also recommend waiting until after 45 years of age to assess cardiovascular risk in healthy individuals. Aboriginal and Torres Strait Islander people should be assessed from age 35 years. These recommendations are based on current evidence of who is more likely to benefit from statin treatment.

AB - Treatment with HMG-CoA reductase inhibitors, commonly known as statins, is beneficial for people at high risk of a cardiovascular event. However, guidelines recommend against routine statin treatment for those with a lower risk. They also recommend waiting until after 45 years of age to assess cardiovascular risk in healthy individuals. Aboriginal and Torres Strait Islander people should be assessed from age 35 years. These recommendations are based on current evidence of who is more likely to benefit from statin treatment.

UR - http://www.scopus.com/inward/record.url?scp=82855175379&partnerID=8YFLogxK

U2 - 10.18773/austprescr.2011.085

DO - 10.18773/austprescr.2011.085

M3 - Article

VL - 34

SP - 169

EP - 172

JO - Australian Prescriber

JF - Australian Prescriber

SN - 0312-8008

IS - 6

ER -